11 results about "Pramipexole" patented technology

A controlled-release multilayer microparticle containing a pharmaceutically active compound, which is intended for oral administration or direct administration in the stomach, which may be done using a liquid pharmaceutical composition containing the microparticle. The microparticle may include: a core that includes the pharmaceutically active compound, which may be pramipexole; a controlled-release intermediate coating layer; and an outmost external protection coating layer surrounding the controlled-release intermediate coating layer. The external protection coating layer may include a mixture of: a hydrophilic gastro-soluble component which is insoluble in aqueous media at a pH of between 6.5 and 7.5; and a hydrophobic and / or insoluble component. Also disclosed are a liquid pharmaceutical composition containing the microparticles, a kit for the preparation of the liquid pharmaceutical composition, a pharmaceutical solid composition reconstitutable as the liquid composition, a process of preparing the liquid composition, and a method for treating disease with the liquid composition.

A pramipexole xinafoate and a sustained-release pharmaceutical formulation thereof are provided. The pramipexole is prepared into its xinafoate, enabling reducing a solubility of the pramipexole salts. A suspension liquid formulation prepared from the pramipexole xinafoate has a good sustained-release effect and good stability, and is suitable for large-scale production.

The present invention describes a combination of an NK1-antagonist and pramipexole, or a pharmaceutically acceptable salt or solvate thereof, which is useful in the treatment of depression, including major depression.

The present invention describes the combination of a 5HT3-antagonist with pramipexole to reduce or eliminate the adverse effects associated with the use of 5 pramipexole and to enable the use of high doses of pramipexole, useful for treating depressive disorders such as major depressive disorder 54 20 24 20 41 79 19 J un 2 02 4 J u n 2 0 2 4 A B S T R A C T 2 0 2 4 2 0 4 1 7 9 1 9

Provided are a long-acting sustained-release pramipexole preparation and a method for preparing same. The long-acting sustained-release pramipexole preparation comprises pramipexole pamoate or pramipexole palmitate, and a polylactic acid-glycolic acid copolymer or polylactic acid. The drug loading capacity of the preparation is 10%-50%. The molar ratio of lactic acid to glycolic acid of the polylactic acid-glycolic acid copolymer is 85:15-95:5. The microsphere is round in shape, smooth in surface and free of pores, and can effectively reduce the early burst release of the drug and solve the problem of high burst release of existing pramipexole pamoate microspheres. Also, the present invention features an effectively prolonged sustained-release period that solves the problem of the short release period of the existing pramipexole pamoate microspheres, and a smaller blood concentration fluctuation that leads to a more stable release.

Abstract The present invention relates to a method for modulating neuropathies. The method comprises: administering to a subject a therapeutically effective amount of doxazosin, a pharmaceutically acceptable salt or an acceptable form thereof, a therapeutically effective amount of pramipexole, a pharmaceutically acceptable salt or an acceptable form thereof, and a 5 therapeutically effective amount of metoprolol, a pharmaceutically acceptable salt or an acceptable form thereof. Abstract 20 26 20 52 65 03 J ul 2 02 6 A b s t r a c t 2 0 2 6 2 0 5 2 6 5 0 3 J u l 2 0 2 6

The present invention describes pharmaceutical combinations of a 5HT3-antagonist, an NK1-antagonist and / or fluoxetine with pramipexole for the treatment of retinal degeneration, including Age-related Macular Degeneration. The present invention also describes methods for treatment of retinal degeneration, including Age-related Macular Degeneration by administration of the pharmaceutical combinations of the invention.

The application belongs to the technical field of medicine synthesis, and particularly relates to a preparation method of tetrahydrozoline. The tetrahydrozoline is synthesized from trifluoromethylaniline and 2-cyanoacetic acid ethyl ester under the action of an alkaline catalyst, the method has mild conditions, simple and easy-to-operate post-treatment and purification, low energy consumption, short working hours, and is suitable for large-scale production.

The invention discloses a purification method and a new crystal form of pregabalin, and the purification method comprises the following steps: (1) enabling pregabalin and organic alkali to form a salt in a ketone solvent, dissolving the salt in the ketone solvent, then cooling the solution to 0-10 DEG C, stirring, separating out a solid, and filtering to obtain a salt wet product of pregabalin; and (2) adding the wet salt product of pregabalin into a mixed solvent composed of a ketone solvent and water, heating to completely dissolve the salt of pregabalin, dropwise adding an acid, adjusting the pH value of the solution to 2.0-5.0, cooling, stirring, and precipitating crystals, in the mixed solvent composed of the ketone solvent and water, the volume ratio of the ketone solvent to the water is 3.5: 1-1.5: 1. The pregabalin crystal obtained by the purification method of the pregabalin is high in purity and high in yield. The obtained pregabalin crystal is in a novel crystal form, is a rhombus or blocky polyhedron, has good fluidity, and is suitable for preparing tablets or capsules.

The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse 5 effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino- 4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone. 10 80 20 24 20 41 67 19 J un 2 02 4 2 0 2 4 A B S T R A C T 2 0 2 4 2 0 4 1 6 7 1 9 J u n 1 0

The invention belongs to the field of biological medicine, and particularly relates to a novel medical application of a dopamine receptor stimulant pramipexole (PPX) as an inhibitor of the activity of sapovirus 2C RNA helicase ATPase, and the inhibitor is pramipexole. In-vitro enzymology experiments prove that the pramipexole can remarkably inhibit the ATP enzyme activity of the SaV 2C RNA helicase, and the inhibition effect of the pramipexole is quantitatively verified through a malachite green-ammonium molybdate colorimetric method. The invention further discloses that pramipexole and SaV-2C RNA helicase form stable interaction (the binding energy is-126.53 kJ / mol) through molecular docking, and the key interaction comprises four hydrogen bonds mediated by Asp47 and Glu48 residues, hydrophobic interaction between the four hydrogen bonds and Leu30, Ala31 and Trp46, and electrostatic force generated by the four hydrogen bonds and Glu48. The invention has the potential of preventing and treating sapovirus infection diseases.